Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kumagai, K.
Right arrow Articles by Ohnoshi, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kumagai, K.
Right arrow Articles by Ohnoshi, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:S107-S109, 1997
© 1997 European Society for Medical Oncology

Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan

K. Kumagai1, T. Takagi1, S. Nakamura2, U. Sawada3, Y. Kura3, F. Kodama4, S. Shimano5, I. Kudoh6, H. Nakamura7, K. Sawada8 and T. Ohnoshi9

1 Hematology-Chemotherapy Division, Chiba Cancer Center Hospital Chiba
2 Third Department of Medicine, School of Medicine, Faculty of Medicine, Kanazawa University Kanazawa
3 First Department of Internal Medicine, Nihon University, School of Medicine Tokyo
4 Hematology-Chemotherapy Division, Kanagawa Cancer Center Hospital Kanagawa
5 Department of Internal Medicine, Gunma Cancer Center Hospital Gunma
6 Department of Internal Medicine, Aomori Prefectual Central Hospital Aomori
7 Second Department of Internal Medicine, School of Medicine, Chiba University Chiba
8 Second Department of Internal Medicine, Hokkaido University, School of Medicine Hokkaido
9 Japan Lymphoma Treatment Study Group Japan

1Correspondence to: T. Takagi, MD Hematology-Chemotherapy Division Chiba Cancer Center Hospital 666-2 Nitona-cho, Chuou-ku Chiba 260 Japan

Background Hepatitis B after the withdrawal of cytotoxic chemotherapy in hepatitis B virus (HBV) carriers is well known and may lead to fatal hepatic failure. We retrospectively analyzed the prevalence of HBV carriers, the incidence, and the risk factors of hepatitis B in the treatment of malignant lymphoma.

Patients and methods HBV carriers were defined as patients with positive HBs-antigen, either with normal or abnormal serum aminotransferase level at patient presentation. Questionnaires to the members of the Japan Lymphoma Treatment Study Group included general information, details about HBV carriers, and further information about hepatitis B.

Results Among 1380 patients collected from eight institutions, 45 patients (3.26%) were determined to be HBV carriers. Hepatitis B developed in 17 of the HBV carrying patients (37.8%). Seven of those 17 (41.2%) died of hepatic failure. Hepatitis developed at a high rate in patients who were negative for HBe-antigen (50%), and who had received second- or third- generation chemotherapy (63.2%).

Conclusions We confirmed that hepatitis B developed with high frequency in HBV carriers with malignant lymphoma. Moreover, hepatitis often resulted in fatal hepatic failure. It is necessary to prevent the hepatitis B developing in HBV carriers when receiving intensive chemotherapy for malignant lymphoma.

chemotherapy, HBV carrier, hepatitis B, malignant lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.